Press release
GM1 Gangliosidosis Treatment Market Growing Rapidly by 2031 - Passage Bio, Lysogene, Sio Gene Therapies, Inc., BioStrategies LC, Sanofi, AZAFAROS, Dorphan S.A.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/gm1-gangliosidosis-treatment-market
The GM1 Gangliosidosis Treatment market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.
GM1 gangliosidosis treatment refers to the therapeutic approaches aimed at managing and alleviating symptoms associated with GM1 gangliosidosis, a rare genetic disorder characterized by the buildup of harmful substances called gangliosides in cells throughout the body. These treatments aim to address the underlying metabolic deficiency caused by mutations in the GLB1 gene, which leads to insufficient production of the enzyme beta-galactosidase. Therapeutic strategies may include supportive care to manage symptoms such as seizures, muscle weakness, and developmental delays, as well as experimental therapies like enzyme replacement therapy (ERT), substrate reduction therapy, gene therapy, and bone marrow transplantation to potentially modify disease progression and improve quality of life for affected individuals.
Forecast Growth Projected:
The Global GM1 Gangliosidosis Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
List of the Key Players in the GM1 Gangliosidosis Treatment Market:
Passage Bio, Lysogene, Sio Gene Therapies, Inc., BioStrategies LC, Sanofi, AZAFAROS, Dorphan S.A., Idorsia Pharmaceuticals Ltd, SphinCS GmbH and Viatris Inc.
Segment Covered in the GM1 Gangliosidosis Treatment Market:
By Type: GM1 Gangliosidosis Type 1 (Infantile), GM1 Gangliosidosis Type 2 (Juvenile), GM1 Gangliosidosis Type 3 (Adult)
By Treatment: Enzyme Replacement Therapy, Gene Therapy, Stem Cell Transplants, Substrate Reduction Therapy, Pharmacological Chaperones, Miglustat, N-Butyl-Deoxynojirimycin (NB-DNJ), Anticonvulsant Drugs
By End User: Hospitals, Ambulatory Surgical Centers, Others
Regional Analysis:
The global GM1 Gangliosidosis Treatment Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
Get Customization in the report as per your requierments: https://datamintelligence.com/customize/gm1-gangliosidosis-treatment-market
Regional Analysis:
The global GM1 Gangliosidosis Treatment Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The GM1 Gangliosidosis Treatment Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of GM1 Gangliosidosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of GM1 Gangliosidosis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Get a Free Sample PDF copy of the report @ https://datamintelligence.com/download-sample/gm1-gangliosidosis-treatment-market
Read Latest Blog: https://www.datamintelligence.com/blogs/top-10-process-automation-companies-worldwide
Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GM1 Gangliosidosis Treatment Market Growing Rapidly by 2031 - Passage Bio, Lysogene, Sio Gene Therapies, Inc., BioStrategies LC, Sanofi, AZAFAROS, Dorphan S.A. here
News-ID: 3580044 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Legal AI Software Market to Reach USD 3.7 Billion by 2030, Driven …
The global Legal AI Software Market reached USD 0.5 billion in 2022 and is projected to reach USD 3.7 billion by 2030, growing at a CAGR of 28.7% during the forecast period 2024-2031, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In September 2025, Thomson Reuters launched its next-generation AI contract review platform, reducing document analysis time by 80% for corporate legal teams.
✅ In August 2025, A coalition of top…
United States AI In Renewable Energy Market to Reach USD 4.85 Billion by 2032, D …
The global AI In Renewable Energy Market reached US$ 0.85 billion in 2024 and is projected to reach US$ 4.85 billion by 2032, growing at a CAGR of 24.32% during the forecast period 2025-2032, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In September 2025, The National Renewable Energy Laboratory (NREL) launched an AI platform that improved solar generation forecasts by 30%, significantly enhancing grid reliability.
✅ In August 2025,…
United States AI In Energy Market Projected to Expand at 33.45% CAGR, Reaching U …
The global AI In Energy Market reached US$ 9.89 billion in 2024 and is projected to reach US$ 99.48 billion by 2032, growing at a CAGR of 33.45% during the forecast period 2025-2032, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In September 2025, Google DeepMind partnered with a major US utility to implement AI for real-time grid optimization, reducing energy losses by 15%.
✅ In…
United States Allergy Immunotherapies Market 2025 | Growth Drivers, Trends & Mar …
Market Size and Growth
The "Global Allergy Immunotherapies Market" is predicted to reach at a high CAGR of 10.4% during the forecast period (2022-2029)
Key Development:
United States: Recent Industry Developments
✅ In September 2025, Sanofi expanded its allergy immunotherapy portfolio by acquiring Ayvakit and early-stage immunology assets for USD 9.1 billion, enhancing its position in severe allergic conditions.
✅ In June 2025, BioVaxys Technology Corp. launched a private placement to raise USD 1.2-1.6…
More Releases for GM1
GM1 Gangliosidosis Market Expected to Reach USD 1.6 Billion by 2034
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme. This results in the accumulation of GM1 gangliosides in cells, primarily affecting the central nervous system. The disease is classified into infantile, juvenile, and adult-onset forms, with infantile GM1 being the most severe and often fatal in early childhood.
Download Full PDF Sample Copy of Market Report…
GM1 Gangliosidosis Market Massive Growth opportunity Ahead
GM1 Gangliosidosis Market Outlook 2024-2034: Expanding Research, Orphan Drug Approvals, and Regional Growth
Introduction
GM1 Gangliosidosis is an ultra-rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to progressive neurodegeneration. Patients experience a range of symptoms-from developmental delays and skeletal abnormalities to severe motor dysfunction and premature mortality. With no approved curative therapy to date, treatment options remain largely supportive.
However, the last decade has witnessed a surge in…
GM1 Gangliosidosis Market Size And Global Industry Forecast 2034
Introduction
The GM1 Gangliosidosis Market is gaining attention as advancements in genetic research and rare disease drug development open new possibilities for this ultra-rare lysosomal storage disorder. GM1 gangliosidosis is caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme and progressive neurodegeneration. With no approved curative treatments currently available, ongoing innovation in gene therapy, enzyme replacement therapy (ERT), and small molecule chaperones is fueling significant…
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies, DelveInsight | Pa …
GM1 Gangliosidosis therapies, such as PBGM01, and others, are expected to boost the GM1 Gangliosidosis Market in the upcoming years.
DelveInsight has launched a new report on "GM1 Gangliosidosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the GM1 Gangliosidosis, historical and forecasted epidemiology as well as the GM1 Gangliosidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover…
GM1 Gangliosidosis Treatment Market
The GM1 Gangliosidosis Treatment Market is expected to witness substantial growth during the forecast period of 2023-2030. Here's an overview of the dynamics, segment analysis, geographical share, and impact of COVID-19 and the Russia-Ukraine war:
Market Overview:
The global GM1 gangliosidosis treatment market is anticipated to experience significant growth due to factors such as rising lysosomal storage disorders, increased research and development activities, and government investments in pharmaceuticals and biotechnology.
Market Dynamics:
Drivers:
Government Investments…
GM1 Gangliosidosis Treatment Market Analysis, Status and Business Outlook 2021 t …
Dec 07, 2021 (Market Intelligence Data) --Global GM1 Gangliosidosis Treatment Market Size, Status, and Forecast 2021-2026. In-depth research accumulated to offer Latest insights about acute features of the global GM1 Gangliosidosis Treatment market. This report provides a detailed overview of key factors in the GM1 Gangliosidosis Treatment Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development. The impact of the COVID-19 outbreak on the industry was…
